# Wolverine legal status: FDA 503A category and compounding access for BPC-157 TB-500 > Wolverine legal status: both BPC-157 TB-500 components are in FDA's 503A Category 2 (effective Sept 29, 2023), with access under active review and a PCAC meeting scheduled July 23-24, 2026. General information, sourced from FDA. Where BPC-157 TB-500 stands in FDA's compounding framework today — and where an active, scheduled review may take it. Present-tense facts, cited to FDA; general information, not legal or medical advice. ## Access is under active FDA review — and may expand in 2026 The Wolverine legal status story is, right now, a story in motion. Both peptides in the BPC-157 TB-500 blend are on the published agenda of an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances being considered for inclusion on the 503A Bulks List [14]. That is the forward-leaning fact: access to these peptides through compounding is being actively evaluated, and the door that is currently closed is the subject of a scheduled review. What that review will decide is unknown. A PCAC meeting is an advisory discussion, not a final FDA decision — no listing, reclassification, or outcome can be assumed, stated, or dated [14]. The honest framing is momentum without a verdict: the question is live, the committee is meeting, and the current legal status is what stands until FDA acts. That current status is unambiguous and present-tense. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved therapeutic indication. Both sit in 503A Category 2 today, which is where this page begins. ## What 503A Category 2 means today Under the Federal Food, Drug, and Cosmetic Act, drug compounding is governed by two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [15]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [15]. FDA's interim policy sorted nominated substances into categories. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [15]. In plain terms: a Category 2 placement means compounding-pharmacy access is currently restricted while FDA's evaluation continues. Both of the Wolverine blend's components are in Category 2. FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [16]. FDA likewise identified "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" as a Category 2 bulk substance effective with the same September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information [16]. FDA's own list entry establishes the relationship between TB-500 and Thymosin Beta-4 [16]. ## Both components are on one scheduled review — no carve-out There is no component carve-out in this blend's regulatory status. Both BPC-157 and TB-500 — the latter being the thymosin beta-4 fragment LKKTETQ — are currently Category 2, and both appear on the published agenda of the single July 23-24, 2026 PCAC meeting as substances being considered for inclusion on the 503A Bulks List [14], [16]. Whatever happens to the access picture for one is being weighed alongside the other, in the same scheduled discussion. That shared posture is the cleanest way to read the [WADA and FDA status](/legal-status#wada) of the pair: two unapproved peptides, both in Category 2 since the same 2023 date, both under one active review. Being discussed by PCAC is a step in evaluation, not a final listing decision [15], [14] — so the present-tense answer to "can these be compounded today" is governed by the Category 2 status, not by the pending agenda. Nothing on this page should be read as asserting that any reclassification has occurred or will occur. The current category for each component is stated as Category 2 because that is the last FDA action confirmable from FDA.gov; the July 2026 meeting is referenced only as a scheduled discussion of substances under evaluation. ## How legally compounded peptide access works In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [15]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [15]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is one route to a licensed-prescriber consultation — not a separate legal status. Telehealth does not expand which substances may be compounded, and it does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription [15]. The ingredient-eligibility caveat is the operative limit. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [15]. Because both BPC-157 and TB-500 are currently Category 2, the eligibility caveat is exactly where the Wolverine blend's access question lives today. This page describes the general regulatory landscape; it is not medical or legal advice, and it is not an offer to sell or supply any substance. ## Access and regulatory questions ### Is Wolverine Legal? Neither component of the Wolverine blend is an FDA-approved drug, and the blend has no approved indication. Both BPC-157 and TB-500 are in FDA's 503A Category 2 (effective September 29, 2023), meaning FDA identified them as bulk substances that may present significant safety risks and they are not within FDA's compounding enforcement-discretion policy [16], [15]. This is general regulatory information, not legal advice or purchasing guidance. ### Can You Get BPC-157 From a Compounding Pharmacy? BPC-157 is currently in 503A Category 2, the category FDA identified as raising significant safety risks and not covered by its enforcement-discretion policy for compounding [16]. Within the general framework, a compounder may use a bulk ingredient only if it is eligible under the 503A/503B rules; a Category 2 placement means access through routine 503A compounding is restricted while that status stands [15]. BPC-157 is also on the July 23-24, 2026 PCAC agenda as a candidate under evaluation [14]. ### What Is the FDA 503A Status of Wolverine? Neither component is FDA-approved. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are in 503A Category 2, effective with FDA's September 29, 2023 update, each cited for potential immunogenicity concerns [16]. Both are on the published agenda of the July 23-24, 2026 PCAC meeting as substances being considered for the 503A Bulks List — a scheduled discussion, not a decision [14]. The blend itself has no approved therapeutic indication. ### Are BPC-157 and TB-500 FDA Approved or Banned by WADA? Neither is FDA-approved for human use; both are in 503A Category 2 as of the September 29, 2023 FDA update [16]. Both constituents are also prohibited by the World Anti-Doping Agency — BPC-157 under the non-approved-substances category and TB-500 / Thymosin Beta-4 under the relevant prohibited peptide and tissue-repair categories — in and out of competition. --- Two repair signals tracked as two bands of cold light — BPC-157's green leg and TB-500's violet leg, each read against its own studies, the convergence left labeled theoretical and the FDA 503A status read first; no clinic behind the aurora and nothing here dispensed.